Pretreatment of Low-Dose and Super-Low-Dose LPS on the Production of *In Vitro* LPS-Induced Inflammatory Mediators

Byeong Suk Chae  
*College of Pharmacy, Woosuk University, Wanju, Korea*

**Abstract**

Pretreatment of low-dose lipopolysaccharide (LPS) induces a hyporesponsive state to subsequent secondary challenge with high-dose LPS in innate immune cells, whereas super-low-dose LPS results in augmented expression of pro-inflammatory cytokines. However, little is known about the difference between super-low-dose and low-dose LPS pretreatments on immune cell-mediated inflammatory and hepatic acute-phase responses to secondary LPS. In the present study, RAW 264.7 cells, EL4 cells, and Hepa-1c1c7 cells were pretreated with super-low-dose LPS (SL-LPS; 50 pg/mL) or low-dose LPS (L-LPS; 50 ng/mL) in fresh complete medium once a day for 2–3 days and then cultured in fresh complete medium for 24 hr or 48 hr in the presence or absence of LPS (1–10 μg/mL) or concanavalin A (Con A). SL-LPS pretreatment strongly enhanced the LPS-induced production of tumor necrosis factor (TNF)-α, interleukin (IL)-6, TNF-α/IL-10, prostaglandin E2 (PGE₂), and nitric oxide (NO) by RAW 264.7 cells compared to the control, whereas L-LPS increased IL-6 and NO production only. SL-LPS strongly augmented the Con A-induced ratios of interferon (IFN)-γ/IL-10 in EL4 cells but decreased the LPS-induced ratios of IFN-γ/IL-10 compared to the control, while L-LPS decreased the Con A- and LPS-induced ratios of IFN-γ/IL-10. SL-LPS enhanced the LPS-induced production of IL-6 by Hepa1c1c7 cells compared to the control, whereas L-LPS increased IL-6 and NO production only. SL-LPS pretreatment strongly enhanced the LPS-induced production of TNF-α, IL-6, IL-10, PGE₂, and NO in RAW 264.7 cells, and the IL-6, IL-1β, and CRP levels in Hepa1c1c7 cells, as well as the ratios of IFN-γ/IL-10 in LPS- and Con A-stimulated EL4 cells compared to L-LPS. These findings suggest that pre-conditioning of SL-LPS may contribute to the mortality to secondary infection in sepsis rather than pre-conditioning of L-LPS.

**Key words:** Endotoxin pretreatment, Proinflammatory cytokines, Prostaglandin E₂, Nitric oxide, Acute-phase protein

**INTRODUCTION**

Endotoxin, a heat-stable cell wall component of gram-negative bacteria, is characterized by robust induction of the systemic inflammatory response in the innate immune system via the Toll-like receptor 4 (TLR4) pathway, which can lead to shock, cell damage, and potentially multiple organ failure (1,2). Endotoxin stimulates the overproduction of pro-inflammatory mediators such as prostaglandin E₂ (PGE₂), tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, interferon (IFN)-γ, and C-reactive protein (CRP), resulting in an acute inflammatory response. Via an inhibitory feedback effect, lipopolysaccharide (LPS) also induces anti-inflammatory cytokines such as IL-1 receptor antagonist, IL-4, IL-10, and IL-13 (3,4). However, pre-exposure of innate immune cells such as macrophages to low-dose LPS (L-LPS, > 10 ng/mL) fails to induce the robust expression of proinflammatory mediators to subsequent endotoxin challenge, a phenomenon known as endotoxin tolerance (5). Endotoxin tolerance leads to a shift away from a pro-inflammatory response, including production of TNF-α, IL-1β, IL-6, and PGE₂, toward a response with key anti-inflammatory features via IL-10 production. Even though endotoxin tolerance is known to protect animals from infection, endotoxin tolerance-induced immunosuppression on the innate immune...
response, which is clinically observed in sepsis patients, is associated with worse outcomes, including mortality (6).

Pretreatment of super-low-dose LPS (SL-LPS, < 100 pg/mL) exhibits increased mortality in response to secondary challenge with a higher dose of LPS (7,8). Endotoxin priming that is characterized by subclinical SL-LPS causes a distinct effect by priming monocytes/macrophages for a more robust response to a secondary LPS challenge, a phenomenon known as the “Shwartzman reaction” (2,7,9). This endotoxin priming response has been shown to augment the LPS-induced production of in vitro pro-inflammatory cytokines such as IL-6 and TNF-α (7,9). SL-LPS removed transcriptional suppressors on the promoters of pro-inflammatory genes, resulting in the mild but persistent expression of pro-inflammatory mediators (10).

The activation of innate immune cells by LPS or LPS-induced inflammatory mediators can result in the development of adaptive immunity and acute-phase responses. The balance between T helper (Th)1 and Th2 cytokines is associated with the ultimate outcome of the cell-mediated immune response. IFN-γ, which is a Th1 cytokine produced by natural killer cells and activated T cells, mediates host defense against infection via activation of macrophages, whereas IL-10 plays a role in the Th2 response (11). Endotoxic shock mortality is also increased via downregulation of the Th1 response and endogenous IFN-γ as well as the innate immune response (12). Endotoxin tolerance is associated with profound impairment in the ability to produce IFN-γ in response to exposure to an endotoxin. In contrast, elevation of endogenous IFN-γ increases the mortality rate, but anti-IFN-γ induces a protective effect from endotoxic shock (13). However, because the immunoparalysis in sepsis has been reported to be partially restored by therapy with recombinant IFN-γ (14), elevated IFN-γ may also play a role in the induction of the T cell-mediated proinflammatory response via an IFN-γ-activated innate immune response.

Increased gut permeability, changes in the composition and diversity of the gut microbiome, and chronic stress have been proposed as possible mechanisms to explain the increased levels of circulating endotoxins in metabolic syndrome (15,16). Metabolic endotoxemia is described as a condition of low-grade elevation of plasma LPS at levels 10–50-times lower than those observed during septic conditions (17). The liver is also associated with high exposure to circulating endotoxins from the gut microbiota, consequently resulting in metabolic endotoxemia (18). Circulating levels of SL-LPS may contribute to the development of a metabolic disorder in the liver via upregulation of acute-phase proteins, which alter the function of the liver and contribute to inflammatory and coagulation processes in sepsis (19). Nevertheless, precisely how preconditioning of SL-LPS in sepsis influences the immune cell-mediated inflammatory response and hepatic acute-phase response to secondary infection remains poorly understood. Therefore, the aim of the present study was to investigate if and how pretreatment of L-LPS and SL-LPS alters the inflammatory response to subsequent high-dose LPS in RAW 264.7 cells, Hepa-1c1c7 cells, and EL4 cells.

**MATERIALS AND METHODS**

**Materials.** RAW 264.7 cells, Hepa-1c1c7 cells, and EL4 cells were purchased from the Korean Cell Bank (Seoul, Korea).

**Cell culture.** RAW 264.7 cells, Hepa-1c1c7 cells, and EL4 cells were maintained in complete Dulbecco’s modified Eagle medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Sigma Chemical Co., St. Louis, MO, USA) and 1× antibiotic/antimycotic (Invitrogen). RAW 264.7 cells and EL4 cells were pretreated with 50 pg/mL or 50 ng/mL LPS in fresh complete medium once a day for 3 days, and the cells were then cultured for 24 hr in fresh complete medium in the presence or absence of 1 μg/mL LPS in RAW 264.7 cells, and with 10 μg/mL LPS or concanavalin A (Con A) (Sigma Chemical Co.) in EL4 cells at 37°C in a humidified atmosphere containing 5% CO2. Hepa-1c1c7 cells were pretreated with 50 pg/mL LPS in fresh complete medium once a day for 2 days, and new Hepa-1c1c7 cells were pretreated with 50 ng/mL LPS once on only the second day. Subsequently, both LPS-pretreated Hepa-1c1c7 cells were cultured in fresh complete medium for 24 hr or 48 hr in the presence of 10 μg/mL LPS. The cell supernatants were then harvested and stored at –70°C for cytokine, CRP, PGE2, and NO assays.

**Cytokine assay.** The concentrations of cytokines in the supernatants harvested from the culture in RAW 264.7 cells, Hepa-1c1c7 cells, and EL4 cells were determined using cytokine monoclonal antibodies (BD Biosciences Pharmingen, CA, USA). All measurements were carried out in triplicate. The results were measured in picograms per milliliter at 450 nm using an enzyme-linked immunoassay (ELISA) microplate reader (Molecular Devices Co., Ltd., CA, USA). The lower limit of sensitivity for each ELISA was ≤ 5 pg/mL.

**PGE2 immunoassay.** The concentrations of PGE2 in the supernatants harvested from the culture in RAW 264.7 cells, Hepa-1c1c7 cells, and EL4 cells were determined using cytokine monoclonal antibodies (BD Biosciences Pharmingen, CA, USA). All measurements were carried out in triplicate. The results were measured in picograms per milliliter at 450 nm using an enzyme-linked immunoassay (ELISA) microplate reader (Molecular Devices Co., Ltd., CA, USA). The lower limit of sensitivity for each ELISA was ≤ 5 pg/mL.

**NO assay.** The concentrations of NO in the supernatants harvested from the culture in RAW 264.7 cells were
Pretreatment of L-LPS and SL-LPS on Inflammation

**Results**

**CRP assay.** The concentrations of CRP in the supernatants harvested from the culture in Hepa1c1c-7 cell were determined using a CRP ELISA kit (R&D Systems Inc., MN, USA) according to the manufacturer instructions. Concentrations of CRP were measured at 450 nm using ELISA. The lower limit of sensitivity for each ELISA was ≤5 pg/mL.

**Statistical analysis.** All data are expressed as means ± standard error of the mean. Experiments were always run in tetraplicate and repeated at least twice. Analysis of variance and Student’s *t*-test were used to determine statistical significance, and *p* < 0.05 was considered to be statistically significant.

**Effects of SL-LPS pretreatment on the LPS-induced production of cytokines by RAW 264.7 cells.** The primary aim of this study was to examine whether pretreatment of 50 pg/mL LPS (SL-LPS) enhances the production of cytokines by RAW 264.7 cells in the presence or absence of high-dose (1 μg/mL) LPS compared to 50 ng/mL LPS (L-LPS) pretreatment. As shown in Fig. 1A, pretreatment of L-LPS and SL-LPS significantly enhanced the production of TNF-α, IL-6, and IL-10 by RAW 264.7 cells.

![Fig. 1. Effects of LPS pretreatment on the LPS-induced production of cytokines in RAW 264.7 cells. (A) Cytokines; (B) TNF-α/IL-10 ratio. RAW 264.7 cells were pretreated with concentrations of LPS 50 pg/mL (SL-LPS) or LPS 50 ng/mL (L-LPS) with fresh complete media once a day for 3ds consequently and the cells were then cultured for 24 hr with fresh complete media in the presence or absence of LPS (1 μg/mL). Concentration of cytokines was measured using ELISA. These experiments were run in tetraplicate and repeated at least twice. Each value represents the mean ± SE. *p < 0.05 and **p < 0.01. Significantly different from the value in each control. #p < 0.05 and ##p < 0.01. Significantly different from the value in each SL-LPS.](image-url)
cells in the absence of high-dose LPS compared to the control and SL-LPS treatments. However, in the presence of high-dose LPS, SL-LPS pretreatment remarkably enhanced the LPS-induced production of TNF-α, IL-6, and IL-10 by RAW 264.7 cells compared to the control, whereas L-LPS increased only the IL-6 level. SL-LPS pretreatment remarkably enhanced the LPS-induced production of TNF-α, IL-6, and IL-10 by RAW 264.7 cells compared to L-LPS. TNF-α/IL-10 ratios in RAW 264.7 cells without high-dose LPS were enhanced in cells that received pretreatment of SL-LPS or L-LPS in a concentration-dependent manner. The TNF-α/IL-10 ratios with LPS in the control, SL-LPS, and L-LPS groups were 0.90, 1.00, and 0.89, respectively (Fig. 1B).

**Effects of SL-LPS pretreatment on the LPS-induced production of PGE2 by RAW 264.7 cells.** We next investigated the effect of pretreatment of SL-LPS and L-LPS on the production of PGE2 by RAW 264.7 cells in the presence or absence of 1 μg/mL LPS. In the absence of high-dose LPS, L-LPS pretreatment remarkably enhanced the production of PGE2 by RAW 264.7 cells compared to the control or SL-LPS group (Fig. 2). However, SL-LPS but not L-LPS pretreatment significantly augmented the LPS-induced production of PGE2 by RAW 264.7 cells compared to the control.

**Effects of SL-LPS pretreatment on the LPS-induced production of NO by RAW 264.7 cells.** The comparison between SL-LPS and L-LPS pretreatment on the LPS-induced production of NO by RAW 264.7 cells in the presence or absence of high-dose LPS (1 μg/mL) is summarized in Fig. 3. The pretreatment of both SL-LPS and L-LPS remarkably enhanced the production of NO by RAW 264.7 cells in the absence of high-dose LPS in a concentration-dependent manner compared to the control. The pretreatments of SL-LPS and L-LPS strongly enhanced the LPS-induced production of NO by RAW 264.7 cells in comparison to the control, but there was no statistically significant difference between the SL-LPS and L-LPS groups.

**Effects of SL-LPS pretreatment on the Con A-induced production of cytokines by EL4 cells.** The effects of SL-LPS and L-LPS pretreatment on the production of cytokines by EL4 cells in the presence or absence of 10 μg/mL Con A are summarized in Fig. 4. The results showed that the Con A-induced productivity of IFN-γ and IL-10 by EL4 cells was significantly increased in the control and L-LPS groups, while IFN-γ was increased but IL-10 was attenuated in the SL-LPS group (Fig. 4A). The IFN-γ/IL-10 ratios in Con A-stimulated EL4 cells in the control, SL-LPS, and L-LPS groups were 3.01, 3.70, and 2.35, respectively (Fig. 4B).

**Effects of SL-LPS pretreatment on the LPS-induced production of cytokines by EL4 cells.** As shown in Fig. 5A, 10 μg/mL LPS remarkably attenuated the production of IL-10 by EL4 cells in the control but, whereas it attenuated IFN-γ but not IL-10 in the SL-LPS and L-LPS groups. The IFN-γ/IL-10 ratios in LPS-stimulated EL4 cells in the control, SL-LPS, and L-LPS groups were 5.83, 1.04, and 0.40, respectively (Fig. 5B).
Effects of SL-LPS pretreatment on the LPS-stimulated production of cytokines and CRP by Hepa-1c1c7 cells. Finally, we investigated the effects of SL-LPS and L-LPS pretreatment on the LPS-induced production of hepatic acute-phase proteins. SL-LPS pretreatment remarkably enhanced the LPS-induced production of IL-6 but did not alter the IL-1β and CRP levels for 24 hr compared to the control, while L-LPS increased IL-6 but decreased IL-1β and CRP levels (Fig. 6). In addition, the LPS-stimulated production of IL-6, IL-1β, and CRP produced by Hepa-1c1c7 cells were remarkably enhanced in the SL-LPS pretreatment compared to those in the L-LPS group.

DISCUSSION

LPS (≥1–300 ng/mL), a potent inducer of inflammation, rapidly causes robust induction of pro- and anti-inflamma-
tory mediators in monocytes/macrophages through the TLR4 pathway (3,4). Endotoxin tolerance, which is induced by pre-exposure of low-dose LPS (> 10 ng/mL in vitro) leads to a refractory state limiting the innate immune response by macrophages to infection or injury via a shift away from a pro-inflammatory response toward an anti-inflammatory response to subsequent secondary challenge with high-dose LPS (8). SL-LPS (1–100 pg/mL in vitro) “primes” monocytes/macrophages for a more robust response and leads to increased mortality to a secondary LPS challenge, a phenomenon known as the “Shwartzman reaction”, which is characterized by platelet aggregation, vascular occlusion, inhibition of fibrinolysis, neutrophil accumulation, endothelial injury, and variable degrees of apoptosis and necrosis in the microvasculature (2,7,9).

One study showed that the endotoxin priming response to SL-LPS resulted in the augmented expression of in vitro pro-inflammatory cytokines such as IL-6 and TNF-α, although SL-LPS failed to activate nuclear factor-κB (20). SL-LPS has been reported to promote the expression of pro-inflammatory mediator genes via a mechanism by which transcriptional suppressors are removed (10). This evidence suggests that LPS induces pro- and anti-inflammatory mediators in monocytes/macrophages, endotoxin tolerance exhibits a shift away from a pro-inflammatory response toward an anti-inflammatory response to secondary challenge with LPS, and SL-LPS may promote a shift toward more of a proinflammatory response through suppression of the anti-inflammatory response.

In the present study, we found that repeated pre-exposure to 50 ng/mL LPS (L-LPS) or 50 pg/mL LPS (SL-LPS) in the absence of subsequent challenge with high-dose LPS enhanced the production of both pro-inflammatory and anti-inflammatory cytokines such as TNF-α, IL-6, and IL-10 in RAW 264.7 cells in a dose-dependent manner. These results indicate that pre-exposure to endotoxin may enhance endotoxin-induced signaling cascades that elicit many pro- and anti-inflammatory pathways in a dose-dependent manner. However, in the presence of high-dose LPS, SL-LPS pretreatment significantly enhanced the LPS-induced production of TNF-α, IL-6, and IL-10 but not IL-1β in RAW 264.7 cells compared to the control, while L-LPS increased only IL-6 but not TNF-α. These data may support recent evidence showing that pretreatment of L-LPS can induce a hyporesponsive state to subsequent secondary challenge with high-dose LPS in innate immune cells, while SL-LPS results in more robust expression of pro-inflammatory cytokines (9). The TNF-α/IL-10 ratio also contributes to the balance of proinflammatory and anti-inflammatory responses. IL-10, which is known as an anti-inflammatory cytokine induced by macrophages in sepsis (21), is dispensable for the development of endotoxin tolerance, but neutralization of IL-10 during the first LPS stimulation induced non-tolerant TNF-α production in response to a secondary endotoxin challenge (22). Our results showed that the TNF-α/IL-10 ratios in LPS-stimulated RAW 264.7 cells in the control, SL-LPS, and L-LPS groups were 0.90, 1.00, and 0.89, respectively. These data indicate that SL-LPS pretreatment may be characterized by endotoxin priming in the innate immune system, while L-LPS is characterized by endotoxin tolerance.

PGE2 mediates the stimulatory effects of LPS in the innate immune system, which is associated with regulation of immune responses and induction of inflammatory
responses (23). In the present study, repeated pre-exposure of L-LPS strongly enhanced the production of PGE\(_2\) by RAW 264.7 cells even without secondary LPS exposure in a dose-dependent manner. In addition, the results obtained from the L-LPS pretreatment support a previous report showing that endotoxin tolerance leads to the suppressed expression of COX2 and production of eicosanoids such as PGE\(_2\) (24). Herein, SL-LPS pretreatment remarkably enhanced the LPS-induced production of PGE\(_2\) by RAW 264.7 cells compared to the control. These observations indicate that endotoxin tolerance may fail to induce the production of PGE\(_2\) by macrophages to the subsequent secondary challenge with high-dose LPS, while endotoxin priming greatly enhanced PGE\(_2\) production.

Endotoxin can initiate systemic and local inflammation, bidirectionally leading to reactive oxygen species production, which can induce tissue damage or interfere with normal metabolism in cells (25,26). The results of the present study demonstrated that repeated pretreatment of low-dose LPS remarkably enhanced the production of NO by RAW 264.7 cells without secondary LPS exposure in a dose-dependent manner. The LPS-induced production of NO by RAW 264.7 cells was remarkably enhanced in the SL-LPS and L-LPS groups compared to the control, with no difference between the SL-LPS and L-LPS groups. These observations suggest that both endotoxin priming and endotoxin tolerance may exhibit NO-dependent effects, including oxidative stress and inflammation.

LPS is a potent T-independent antigen promoting humoral immune responses, suggesting that LPS can lead to the downregulation of cell-mediated immunity with a shift in the Th1/Th2 balance toward Th2 and allergic inflammation (27). Endotoxin tolerance also induces suppression of the T-cell mediated immune response (28). Endotoxin tolerance resulted in the reduced production of IL-2 and IFN-\(\gamma\) and the increased production of IL-4 and IL-6 (12,29), indicating that endotoxin tolerance may attenuate cell-mediated immunity with a shift in the Th1/Th2 balance toward Th2. Con A is a selective T cell mitogen relative to its effects on B cells. Herein, Con A-induced productivity of IFN-\(\gamma\) by EL4 cells was strongly increased in the control, SL-LPS, and L-LPS pretreatment, while Con A-induced productivity of IL-10 increased in the control and L-LPS groups but was attenuated in the SL-LPS group. In other words, IFN-\(\gamma\)/IL-10 ratios in Con A-stimulated EL4 cells were 2.6-fold higher in the SL-LPS group than in the L-LPS group. These data indicate that pretreatments of SL-LPS and L-LPS may contribute to the downregulation of cell-mediated immunity with a shift in the Th1/Th2 balance toward Th2 such as allergic inflammation to subsequent LPS challenge. At the same time, SL-LPS pretreatment may contribute to the induction of a greater Th1-mediated proinflammatory response compared to L-LPS, consequently leading to a proinflammatory response in innate immune cells. However, further studies are needed to reveal the precise mechanism of the role of IFN-\(\gamma\) in the effects of SL-LPS and L-LPS.

The liver, which is a metabolic and immunologic organ, can rapidly activate immunity and promote the production of acute-phase proteins in response to infections or tissue damage, leading to systemic inflammation (31,32). The LPS-induced production of acute-phase proteins by hepatocytes contributes to systemic inflammation and exacerbates the accumulation of oxidative damage products in the liver (33-35). Preconditioning by L-LPS prevented subsequent LPS-induced severe liver injury via Nrf2 activation in mice (36). Acute-phase proteins, including IL-6, IL-1\(\beta\), and CRP, are well-known markers of inflammation and potent predictors of future metabolic syndrome and cardiovascular disease (37,38). IL-6 and IL-1\(\beta\) are considered to be strong inducers of CRP in the liver (39). IL-6 and CRP also mediate the development of hepatic insulin resistance and type 2 diabetes (40). However, the effects of pretreatment of SL-LPS and L-LPS on LPS-induced production of acute-phase proteins have been poorly understood to date. The present study indicates that SL-LPS pretreatment may deteriorate hepatic inflammation and the acute-phase response to secondary infection via enhanced production of IL-6, while the L-
LPS decline partly occurs by the attenuated production of IL-1β and CRP, despite elevated IL-6 levels. In addition, induction of metabolic inflammation and acute-phase responses to secondary endotoxin may be dependent on the preconditioning of low-grade endotoxia with SL-LPS rather than L-LPS.

In conclusion, these findings suggest that pre-conditioning of SL-LPS may contribute to the mortality to secondary infection in sepsis rather than the pre-conditioning of L-LPS.

Received October 31, 2017; Revised December 17, 2017; Accepted December 20, 2017

REFERENCES

1. Alexander, C. and Rietschel, E.T. (2001) Bacterial lipopolysaccharides and innate immunity. J. Endotoxin Res., 7, 167-202.
2. Patel, P.N., Shah, R.Y., Ferguson, J.F. and Reilly, M.P. (2015) Human experimental endotoxia in modeling the pathophysiology, genomics, and therapeutic approaches of innate immunity in cardiovascular and metabolic diseases. Arterioscler. Thromb. Vasc. Biol., 35, 525-534.
3. Offenbacher, S. and Salvi, G.E. (1999) Induction of prostaglandin release from macrophages by bacterial endotoxin. Clin. Infect. Dis., 28, 505-513.
4. Kawai, T. and Akira, S. (2007) Signaling to NF-kappaB by Toll-like receptors. Trends Mol. Med., 13, 460-469.
5. Biswas, S.K. and Lopez-Collazo, E. (2009) Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol., 30, 475-487.
6. Cheng, S.C., Scicluna, B.P., Arts, R.J., Gresnigt, M.S., Lachner, A., Eizner, E., Kox, M., Manjeri, G.R., Wagenaaars, J.A., Cremer, O.L., Leentjens, J., van der Meer, A.J., van de Verdonk, F.L., Bonten, M.J., Schultz, M.J., Willems, P.H., Pickers, P., Joosten, L.A., van der Poll, T. and Netea, M.G. (2016) Broad defects in the energy metabolism of leukocytes underlie immunosuppression in sepsis. Nat. Immunol., 17, 406-413.
7. Deng, H., Maitra, U., Morris, M. and Li, L. (2013) Molecular mechanisms responsible for the priming of macrophage activation. J. Biol. Chem., 288, 3897-3906.
8. Chen, K., Geng, S., Yuan, R., Diao, N., Upchurch, Z. and Li, L. (2015) Super-low dose endotoxin pre-conditioning exacerbates sepsis mortality. EBioMedicine, 2, 324-333.
9. Morris, M. and Li, L. (2012) Molecular mechanisms and pathophysiological consequences of endotoxin tolerance and priming. Arch. Immunol. Ther. Exp. (Warsz), 60, 13-18.
10. Maitra, U., Gan, L., Chang, S. and Li, L. (2011) Low-dose endotoxin induces inflammation by selectively removing nuclear receptors and activating CCAAT/enhancer-binding protein δ. J. Immunol., 186, 4467-4473.
11. Romagnani, S. (2000) T-cell subsets (Th1 versus Th2). Ann. Allergy Asthma Immunol., 85, 9-18.
12. Balkhy, H.H. and Heinzell, F.P. (1999) Endotoxin fails to induce IFN-gamma in endotoxin-tolerant mice: deficiencies in both IL-12 heterodimer production and IL-12 responsiveness. J. Immunol., 162, 3633-3638.
13. Heinzell, F.P. (1990) The role of IFN-gamma in the pathology of experimental endotoxemia. J. Immunol., 145, 2920-2924.
14. Kox, W.J., Volk, T., Kox, S.N. and Volk, H.D. (2000) Immunomodulatory therapies in sepsis. Intensive Care Med., 26, S124-S128.
15. Boutagy, N.E., McMillan, R.P., Friisard, M.I. and Hulver, M.W. (2016) Metabolic endotoxemia with obesity: is it real and is it relevant? Biochimie, 124, 11-20.
16. Tarasenko, T.N. and McGuire, P.J. (2017) The liver is a metabolic and immunologic organ: a reconsideration of metabolic compensation due to infection in inborn errors of metabolism (IEM). Mol. Genet. Metab., 121, 283-288.
17. Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A.M., Fava, F., Tuohy, K.M. and Chabo, C. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes, 56, 1761-1772.
18. Dhaenaut, J.F., Marin, N., Mignon, A. and Vinsonneau, C. (2001) Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit. Care Med., 29, S42-S47.
19. Dhainaut, J.F., Marin, N., Mignon, A. and Vinsonneau, C. (2001) Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit. Care Med., 29, S42-S47.
20. Maitra, U., Gan, L., Chang, S. and Li, L. (2011) Low-dose endotoxin induces inflammation by selectively removing nuclear receptors and activating CCAAT/enhancer-binding protein δ. J. Immunol., 186, 4467-4473.
21. Aggarwal, N.R., Tsuchima, K., Eto, Y., Tripathi, A., Mandke, P., Mock, J.R., Garibaldi, B.T., Singer, B.D., Sidhaye, V.K., Horton, M.R., King, L.S. and D’Alessio, F.R. (2014) Immunological priming requires regulatory T cells and IL-10-producing macrophages to accelerate resolution from severe lung inflammation. J. Immunol., 192, 4453-4464.
22. Zhou, F., Ciric, B., Li, H., Yan, Y., Li, K., Cullimore, M., Lauretti, E., Gonnella, P., Zhang, G.X. and Rostami, A. (2012) IL-10 deficiency blocks the ability of LPS to regulate expression of tolerance-related molecules on dendritic cells. Eur. J. Immunol., 42, 1449-1458.
23. Kalinski, P. (2012) Regulation of immune responses by prostaglandin E2. J. Immunol., 188, 21-28.
24. Fernando, L.P., Fernando, A.N., Ferlito, M., Halushka, P.V. and Cook, J.A. (2000) Suppression of Cox-2 and TNF-alpha mRNA in endotoxin tolerance: effect of cycloheximide, antinomycin D, and okadaic acid. Shock, 14, 128-133.
25. Ando, K. and Fujita, T. (2009) Metabolic syndrome and oxidative stress. Free Radic. Biol. Med., 47, 213-218.
26. Hotamisligil, G.S. (2006) Inflammation and metabolic disorders. Nature, 444, 860-867.
27. Kumar, S. and Adhikari, A. (2017) Dose-dependent immunomodulating effects of endotoxin in allergic airway inflammation. Innate Immun., 23, 249-257.
28. Matsushita, H., Ohta, S., Shiraishi, H., Suzuki, S., Arima, K., Toda, S., Tanaka, H., Nagai, H., Kimoto, M., Inokuchi, A. and Izuhara, K. (2010) Endotoxin tolerance attenuates
airway allergic inflammation in model mice by suppression of the T-cell stimulatory effect of dendritic cells. *Int. Immunol.*, **22**, 739-747.

29. Chae, B.S. (2002) Comparative study of the endotoxemia and endotoxin tolerance on the production of Th cytokines and macrophage interleukin-6: differential regulation of indomethacin. *Arch. Pharm. Res.*, **25**, 910-916.

30. Poujol, F., Monneret, G., Gallet-Gorius, E., Pachot, A., Textoris, J. and Venet, F. (2017) *Ex vivo* Stimulation of Lymphocytes with IL-10 mimics sepsis-induced intrinsic T-cell alterations. *Immunol. Invest.*, **28**, 1-15.

31. Heymann, F. and Tacke, F. (2016) Immunology in the liver--from homeostasis to disease. *Nat. Rev. Gastroenterol. Hepatol.*, **13**, 88-110.

32. Bauer, M., Press, A.T. and Trauner, M. (2013) The liver in sepsis: patterns of response and injury. *Curr. Opin. Crit. Care.*, **19**, 123-127.

33. Saad, B., Frei, K., Scholl, F.A., Fontana, A. and Maier, P. (1995) Hepatocyte-derived interleukin-6 and tumor-necrosis factor alpha mediate the lipopolysaccharide-induced acute-phase response and nitric oxide release by cultured rat hepatocytes. *Eur. J. Biochem.*, **229**, 349-355.

34. Panesar, N., Tolman, K. and Mazuski, J. E. (1999) Endotoxin stimulates hepatocyte interleukin-6 production. *J. Surg. Res.*, **85**, 251-258.

35. Mohamed, J., Nazratun Naflizah, A.H., Zariyantey, A.H. and Budin, S.B. (2016) Mechanisms of diabetes-induced liver damage: the role of oxidative stress and inflammation. *J. Sultan Qaboos Univ. Med..*, **16**, e132-e141.

36. Nakasone, M., Nakaso, K., Horikoshi, Y., Hanaki, T., Kitagawa, Y., Takahashi, T., Inagaki, Y. and Matsura, T. (2016) Preconditioning by low dose LPS prevents subsequent LPS-induced severe liver injury via Nrf2 activation in mice. *Yonago Acta Med.*, **59**, 223-231.

37. Dupuy, A.M., Terrier, N., Sénecal, L., Morena, M., Leray, H., Canaud, B. and Cristol, J.P. (2003) Is C-reactive protein a marker of inflammation? *Nephrologie*, **24**, 337-341.

38. Ridker, P.M. and Morrow, D.A. (2003) C-reactive protein, inflammation, and coronary risk. *Cardiol. Clin.*, **21**, 315-325.

39. Kramer, F., Torzewski, J., Kamenz, J., Veit, K., Hombach, V., Dedio, J. and Ivashchenko, Y. (2008) Interleukin-1beta stimulates acute phase response and C-reactive protein synthesis by inducing an NFkappaB- and C/EBPbeta-dependent autocrine interleukin-6 loop. *Mol. Immunol.*, **45**, 2678-2689.

40. Pradhan, A.D., Manson, J.E., Rifai, N., Buring, J.E. and Ridker, P.M. (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA*, **286**, 327-334.